Citigroup Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz has initiated coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and a price target of $42.
November 07, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has initiated coverage on BridgeBio Pharma with a Buy rating and a price target of $42, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Citigroup's Buy rating and price target of $42 for BridgeBio Pharma suggest a positive outlook for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100